Zhou Xiangyan, Wang Sixing, Wang Xiaohui, Chen Xinran, Zhou Pei, Ma Kai, Zhang Peng
Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
First Clinical Department, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Nutr. 2025 Aug 6;12:1634548. doi: 10.3389/fnut.2025.1634548. eCollection 2025.
Depression is a significant public health issue which exerts profound psychological and social impacts on both individuals and society. However, existing therapeutic strategies often exhibit limited efficacy. Accumulating evidence underscores the vital role of gut microbiota in the pathophysiology of depression through the microbiota-gut-brain (MGB) axis. This involves multiple mechanisms, including short-chain fatty acid (SCFA) metabolism, communication via the vagal nerve, regulation of the hypothalamic-pituitary-adrenal (HPA) axis, and immune-inflammatory interactions. This review provides a comprehensive review of the mechanisms through which gut microbiota influences depression via the MGB axis. It synthesizes recent achievements in this field and evaluates the potential of microbiome-targeted therapies for depression treatment. Furthermore, it outlines future research directions to establish a theoretical framework for novel therapeutic approaches and to foster the development of this area.
抑郁症是一个重大的公共卫生问题，对个人和社会都产生深远的心理和社会影响。然而，现有的治疗策略往往疗效有限。越来越多的证据强调了肠道微生物群通过微生物-肠道-脑（MGB）轴在抑郁症病理生理学中的重要作用。这涉及多种机制，包括短链脂肪酸（SCFA）代谢、通过迷走神经进行的通讯、下丘脑-垂体-肾上腺（HPA）轴的调节以及免疫-炎症相互作用。本综述全面回顾了肠道微生物群通过MGB轴影响抑郁症的机制。它综合了该领域的最新成果，并评估了针对微生物群的疗法在抑郁症治疗中的潜力。此外，它概述了未来的研究方向，以建立新治疗方法的理论框架并促进该领域的发展。
